Drug Trial Radar · NCT01081678
Study To Assess FRacTure Healing With SclerosTin Antibody - Hip
Last checked: Nov 20, 2026Latest source record: Sep 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
332
Actual
Start
Jun 20, 2010
Primary completion
Jun 30, 2012
Study completion May 10, 2013
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Mar 5, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 55 years, up to 95 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an international, multi-center study to determine the efficacy, safety, and tolerability of romosozumab (AMG 785) in adults with a fresh unilateral hip fracture, status post surgical fixation.
Conditions
- Fracture Healing
Interventions
PlaceboDrug
Administered by subcutaneous (under the skin) injection
RomosozumabDrug
Administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Timed-Up-and-Go (TUG) Over Week 6 Through Week 20Time frame: Weeks 6, 12, 16, and 20
Locations
99 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Pomona, California
Research Site
Aurora, Colorado
Research Site
Denver, Colorado
Research Site
Indianapolis, Indiana
Research Site
Woodbury, Minnesota
Research Site
St Louis, Missouri
Research Site
Brooklyn, New York
Research Site
Rochester, New York
Research Site
Altoona, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
State College, Pennsylvania
Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Liverpool, New South Wales, Australia
Research Site
Footscray, Victoria, Australia
Research Site
Bruges, Belgium
Research Site
Genk, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Research Site
Liège, Belgium
Research Site
Blagoevgrad, Bulgaria
Research Site
Pleven, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Red Deer, Alberta, Canada
Research Site
Cambridge, Ontario, Canada
Research Site
Guelph, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Waterloo, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Ã…rhus C, Denmark
Research Site
Hvidovre, Denmark
Research Site
København NV, Denmark
Research Site
Viborg, Denmark
Research Site
Tallinn, Estonia
Research Site
Tartu, Estonia
Research Site
Kuopio, Finland
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.